Do you want to read an article? Please log in or register.
Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease
Interstitial Lung Disease
RECOMMENDED
Related content
RECOMMENDED
Interstitial Lung DiseasePneumonia
[New developments in systemic sclerosis-associated interstitial lung disease]
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
Rev Med Suisse
Humair G, Daccord C, Beigelman-Aubry C, Lazor R
RECOMMENDED
Interstitial Lung Disease
Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial
★ 2
Recommended by
Dr Martin Frey, Faculty Member
Ann Rheum Dis.
Seibold JR, Maher TM, Highland KB, Assassi S, Azuma A, Hummers LK, Costabel U, von Wangenheim U, Kohlbrenner V, Gahlemann M, Alves M, Distler O, SENSCIS trial investigators
doi: 10.1136/annrheumdis-2020-217331.
CoughInterstitial Lung Disease
Cough is less common and less severe in systemic sclerosis-associated interstitial lung disease compared to other fibrotic interstitial lung diseases
Respirology.
Cheng JZ, Wilcox PG, Glaspole I, Corte TJ, Murphy D, Hague CJ, Ryerson CJ
doi: 10.1111/resp.13084.
RECOMMENDED
Interstitial Lung Disease
Systemic sclerosis-associated interstitial lung disease
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
Lancet Respir Med.
Perelas A, Silver RM, Arrossi AV, Highland KB
doi: 10.1016/S2213-2600(19)30480-1.
RECOMMENDED
Further Publications
Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Lancet Respir Med
Highland KB, Distler O, Kuwana M, Allanore Y, Assassi S, Azuma A, Bourdin A, Denton CP, Distler JHW, Hoffmann-Vold AM, Khanna D, Mayes MD, Raghu G, Vonk MC, Gahlemann M, Clerisme-Beaty E, Girard M, Stowasser S, Zoz D, Maher TM, SENSCIS trial investigators.
doi: 10.1016/S2213-2600(20)30330-1
PHARMA NEWS
Interstitial Lung Disease
Phase III study showed nintedanib slows the loss of pulmonary function in people living with systemic sclerosis associated ILD1
doi: 10.1056/NEJMoa1903076
PHARMA NEWS
Interstitial Lung Disease
Boehringer Ingelheim announces FDA and EMA regulatory submission for nintedanib in systemic sclerosis associated ILD
RECOMMENDED
Interstitial Lung Disease
The Spectrum of Interstitial Lung Disease Associated with Autoimmune Diseases: Data of a 3.6-Year Prospective Study from a Referral Center of Interstitial Lung Disease and Lung Transplantation
★ 2
Recommended by
Dr Martin Frey, Faculty Member
J Clin Med.
Atienza-Mateo B, Remuzgo-Martínez S, Mora Cuesta VM, Iturbe-Fernández D, Fernández-Rozas S, Prieto-Peña D, Calderón-Goercke M, Corrales A, Blanco Rodríguez GB, Gómez-Román JJ, González-Gay MÁ, Cifrián JM
doi: 10.3390/jcm9061606.
Interstitial Lung Disease
Pneumoproteins KL-6 and CCL-18 Predict Progression of Interstitial Lung Disease in Systemic Sclerosis
Arthritis Rheumatol.
Volkmann ER, Tashkin DP, Kuwana M, Li N, Roth MD, Charles J, Hant FN, Bogatkevich GS, Akter T, Kim G, Goldin J, Khanna D, Clements PJ, Furst DE, Elashoff RM, Silver RM, Assassi S
doi: 10.1002/art.41020.